BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Developing drugs for neurodegeneration and other diseases in acade
 mia\, industry and in-between - John Skidmore\, Alzheimer’s Research UK 
 Cambridge Drug Discovery Institute
DTSTART:20180221T103000Z
DTEND:20180221T113000Z
UID:TALK101590@talks.cam.ac.uk
CONTACT:Patrick Flagmeier
DESCRIPTION:Over recent decades\, medicinal chemists have proven to be ver
 y efficient at finding small molecules to modulate the activity of enzyme 
 and receptor targets but this has not always led to the development of new
  drugs. Drawing on examples from industry\, academia and the not-for-profi
 t sector\, ways in which this gap can be bridged will be explored. Firstly
 \, the importance of expanding the range of druggable targets will be disc
 ussed using the example of RAD51-BRCA2 protein-protein interaction inhibit
 ors. Secondly\, the challenge of identifying druggable targets to drive a 
 reduction in the level of the misfolded proteins thought to cause many neu
 rodegenerative diseases will be explored\, using examples from the Alzheim
 er's Research UK Cambridge Drug Discovery Institute.
LOCATION:Department of Chemistry\, Cambridge\, Unilever lecture theatre
END:VEVENT
END:VCALENDAR